Lawrence Fong, M.D. is the Bezos Distinguished Scholar, director of the Immunotherapy Integrating Research Center, and director of the Immunotherapy Clinic at the Fred Hutchinson Cancer Center in Seattle. Prior to this, he was the founding director of the Cancer Immunotherapy Program at UCSF.  He received a B.A. from Columbia University and a M.D. from Stanford University. As a physician-scientist, Dr. Fong has been involved in both pre-clinical and clinical studies of multiple cancer immunotherapies including anti-CTLA-4 and anti-PD-(L)1 antibodies that are now FDA-approved. This work includes first-in-human trials with cancer vaccines, anti-CTLA-4, adenosine antagonists, and T cell engagers. His laboratory utilizes multi-omic single cell approaches to examine the mechanisms that underlie response and resistance to the different immunotherapies. He is an elected member of the Alpha Omega Alpha Honor Society and the American Society for Clinical Investigation. He is also an NIH Outstanding Investigator Award recipient. He has served on Scientific Steering Committees for the NCI and Programmatic Review Committees for the DOD. He has also served as inaugural senior editors for the Journal of Immunotherapy of Cancer and Cancer Immunology Research.